Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00180856 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Radiofrequency Ablation of Lung Tumors

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study Status, Sponsor/Collaborators, Oversight, Referencesv2
  2. Study First Submitted
Radiofrequency ablation has achieved impressive results in the treatment of unresectable primary and metastatic liver cancer. Animal studies have demonstrated that radiofrequency can fully ablate lung tumors in animal models. We set up a prospective study to evaluate the local efficacy of radiofrequency ablation of lung neoplasms. The aim of the study is to prospectively evaluate local efficacy with a minimal follow-up of one year, tolerance, lung disease-free survival and survival after radiofrequency ablation of lung tumors (primary lung cancer or lung metastases).
Trial Details
NCT Number NCT00180856
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Conditions
(from sponsor)		 Lung Cancer, Metastasis
Related terms Lung Neoplasms, Neoplasm Metastasis
Enrollment 60 participants
Start Date
Updated on ClinicalTrials.gov